Do Quality-Adjusted Life Years Discriminate Against the Elderly? An Empirical Analysis of Published Cost-Effectiveness Analyses

被引:4
|
作者
Xie, Feng [1 ,2 ,5 ]
Zhou, Ting [1 ,3 ]
Humphries, Brittany [1 ]
Neumann, Peter J. [4 ]
机构
[1] McMaster Univ, Fac Hlth Sci, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada
[2] McMaster Univ, Fac Hlth Sci, Ctr Hlth Econ & Policy Anal, Hamilton, ON, Canada
[3] China Pharmaceut Univ, Ctr Pharmacoecon & Outcome Res, Nanjing, Peoples R China
[4] Tufts Med Ctr, Inst Clin Res & Hlth Policy Studies, Ctr Evaluat Value & Risk Hlth, Boston, MA USA
[5] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, 1280 Main St West, Hamilton, ON L8S 4L8, Canada
关键词
age; cost-effectiveness analysis; elderly; discrimination; quality-adjusted life-year;
D O I
10.1016/j.jval.2024.03.011
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Critics of quality-adjusted life-years argue that it discriminates against older individuals. However, little empirical evidence has been produced to inform this debate. This study aimed to compare published cost-effectiveness analyses (CEAs) on patients aged >= 65 years and those aged <65 years. Methods: We used the Tufts Cost-Effectiveness Analysis Registry to identify CEAs published in MEDLINE between 1976 and 2021. Eligible CEAs were categorized according to age (>= 65 years vs <65 years). The distributions of incremental cost-effectiveness ratios (ICERs) were compared between the age groups. We used logistic regression to assess the association between age groups and the cost-effectiveness conclusion adjusted for confounding factors. We conducted sensitivity analyses to explore the impact of mixed age and age-unknown groups and all ICERs from the same CEAs. Subgroup analyses were also conducted. Results: A total of 4445 CEAs categorized according to age <65 years (n = 3784) and age >= 65 years (n = 661) were included in the primary analysis. The distributions of ICERs and the likelihood of concluding that the intervention was cost-effective were similar between the 2 age groups. Adjusted odds ratios ranged from 1.132 (95% CI 0.930-1.377) to 1.248 (95% CI 0.970-1.606) (odds ratio >1 indicating that CEAs for age >= 65 years were more likely to conclude the intervention was cost-effective than those for age <65 years). Sensitivity and subgroup analyses found similar results. Conclusion: Our analysis found no systematic differences in published ICERs using quality-adjusted life-years between CEAs for individuals aged >= 65 years and those for individuals aged <65 years.
引用
收藏
页码:706 / 712
页数:7
相关论文
共 50 条
  • [11] A COST-EFFECTIVENESS ANALYSIS OF VITAMIN D TESTING AND SUPPLEMENTATION STRATEGIES ON QUALITY-ADJUSTED LIFE-YEARS IN PEDIATRIC RENAL TRANSPLANT RECIPIENTS
    Desai, A. M.
    Goebel, J. W.
    Cavanaugh, T. M.
    VALUE IN HEALTH, 2013, 16 (03) : A191 - A191
  • [12] Reverse-total shoulder arthroplasty cost-effectiveness: A quality-adjusted life years comparison with total hip arthroplasty
    Bachman, Daniel
    Nyland, John
    Krupp, Ryan
    WORLD JOURNAL OF ORTHOPEDICS, 2016, 7 (02): : 123 - 127
  • [13] ETHICAL IMPLICATIONS OF QUALITY ADJUSTING AND DISCOUNTING LIFE YEARS IN COST-EFFECTIVENESS ANALYSES INVOLVING THE ELDERLY
    PANZER, RJ
    RICHARDSON, WS
    ISSELHARDT, BJ
    NAPODANO, RJ
    MEDICAL DECISION MAKING, 1986, 6 (04) : 273 - 273
  • [14] Moving Beyond Quality-Adjusted Life-Years in Elderly Care: How Can Multicriteria Decision Analysis Complement Cost-Effectiveness Analysis in Local-Level Decision Making
    Hoedemakers, Maaike
    Tsiachristas, Apostolos
    Rutten-van Molken, Maureen
    VALUE IN HEALTH, 2022, 25 (10) : 1717 - 1725
  • [15] On cost-effectiveness analysis, quality-adjusted life years, and cost-effectiveness threshold values of gemcitabine plus nab-paclitaxel versus gemcitabine alone in metastatic pancreatic cancer in the French setting
    Lazzaro, Carlo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [16] QALY-time: experts' view on the use of the quality-adjusted LIFE year in COST-effectiveness analysis in palliative care
    Wichmann, Anne B.
    Goltstein, Lia C. M. J.
    Obihara, Ndidi J.
    Berendsen, Madeleine R.
    Van Houdenhoven, M.
    Morrison, R. Sean
    Johnston, Bridget M.
    Engels, Y.
    BMC HEALTH SERVICES RESEARCH, 2020, 20 (01)
  • [17] QALY-time: experts’ view on the use of the quality-adjusted life year in cost-effectiveness analysis in palliative care
    Anne B. Wichmann
    Lia C. M. J. Goltstein
    Ndidi J. Obihara
    Madeleine R. Berendsen
    M. Van Houdenhoven
    R. Sean Morrison
    Bridget M. Johnston
    Y. Engels
    BMC Health Services Research, 20
  • [18] Discriminatory Properties of the Quality-Adjusted Life Year Based Cost-Effectiveness Analyses for Patients With Disabilities: A Duchenne Muscular Dystrophy Case Study
    Klimchak, Alexa C.
    Sedita, Lauren E.
    Perfetto, Eleanor M.
    Gooch, Katherine L.
    Malone, Daniel C.
    VALUE IN HEALTH, 2024, 27 (12) : 1641 - 1647
  • [19] Application of cost utility and quality-adjusted life years analyses to monitored anesthesia care for sedation only
    Dexter, F
    JOURNAL OF CLINICAL ANESTHESIA, 1996, 8 (04) : 286 - 288
  • [20] DOES COST-EFFECTIVENESS ANALYSIS DISCRIMINATE AGAINST PATIENTS WITH SHORTER LIFE EXPECTANCY?
    Paulden, M.
    Culyer, A. J.
    VALUE IN HEALTH, 2011, 14 (03) : A12 - A12